LEQEMBI

This brand name is authorized in United States

Active ingredients

The drug LEQEMBI contains one active pharmaceutical ingredient (API):

1 Lecanemab
UNII 12PYH0FTU9 - LECANEMAB

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Lecanemab reduces amyloid beta plaques, as evaluated in studies.

Read about Lecanemab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
LEQEMBI Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N06DX04 N Nervous system → N06 Psychoanaleptics → N06D Anti-dementia drugs → N06DX Other anti-dementia drugs
Discover more medicines within N06DX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: US FDA, National Drug Code Identifier(s): 62856-212, 62856-215

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.